ABSTRACT
BACKGROUND: The sacral nerve stimulation (SNS) can be performed in the screening phase under local anaesthesia. Implantation of the tined-lead electrodes is usually performed in an inpatient setting under general anaesthesia. An outpatient procedure for both PNE and implantation of the electrodes offers decisive advantages with respect to the accuracy of electrode placement. MATERIALS AND METHODS: From 2006 to 2011 a total of 51 patients was treated with SNS in an outpatient setting. RESULTS: Of 51 patients having the PNE, in four patients the procedure could not successfully be completed. In 39 of the 47 patients screened, the testing was positive. Eight times the screening was negative. The functional results show a significant decline in the Cleveland scores from 14.9 to 6.4. The manometric resting pressure improved from 23.4 mmHg to 43.81 mmHg, the squeezing pressure improved from 42.2 mmHg to 76.12 mmHg. Due to patients' perception and according to the response on the stimulus, the electrodes were placed on the left in S4 11 times, 23 times in the left S3, 3 times in the right S3, once in the left S2 and once in the right S2. CONCLUSION: CT-guided electrode placement is safe for temporary (subchronic) and permanent (chronic) sacral nerve stimulation and provides a valuable means for placement of the stimulating material.
Subject(s)
Electric Stimulation Therapy/methods , Electrodes, Implanted , Fecal Incontinence/physiopathology , Fecal Incontinence/therapy , Multidetector Computed Tomography/methods , Spinal Nerves/physiopathology , Surgery, Computer-Assisted/methods , Adult , Aged , Aged, 80 and over , Ambulatory Surgical Procedures , Anesthesia, General , Anesthesia, Local , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Percutaneous endoscopic gastrostomy (PEG) has been classified to date as a high-risk procedure (ASGE guidelines). Coagulopathies, thrombocyte aggregation inhibitors (Aspirin, clopidogrel etc.) and phenprocoumone or warfarin are considered to be contraindications. The study examined for the first time the risk factors in patients with and without concurrent anticoagulation. METHODS: Between 2001 and 2007 PEGs were placed in 450 patients with neurological diseases at the University Hospital for General and Visceral Surgery in Freiburg and studied prospectively during hospitalization. The patients were divided into 3 groups: group 1 controls (n=50, no anticoagulation), group 2 low-molecular-weight heparin (LMWH) prophylaxis (n=152) and group 3 therapeutic anticoagulation (unfractionated heparin, phenprocoumone, therapeutic LMWH, aspirin, clopidorel and combinations, n=248). Univariate analyses were performed to determine risk factors for the occurrence of infection, bleeding and peritonitis. The p-values (p), odds ratios (OR) and 95% confidence intervals (CI) are given. RESULTS: The average hospitalization time was 27.4 days (range 1-268 days) and hospital mortality was 6%. There were no cases of death due to the PEG. Complications included peristomal infections (n=30, 6.6%) and peritonitis (n=6, 1.3%). Post-PEG bleeding did not occur either with or without anticoagulation. The investigated risk factors showed no statistically significant values with respect to prognosis for these complications. Multivariate testing could not be carried out due to the low number of complications. CONCLUSION: Complications of PEG placement with the method used here are rare. An increased risk of bleeding during therapeutic anticoagulation was not observed. In our opinion the present data indicate that PEG placement can be carried out in selected patients with increased risk of thromboembolism without discontinuation of anticoagulation.
Subject(s)
Anticoagulants/administration & dosage , Gastrostomy/methods , Postoperative Complications/etiology , Thromboembolism/drug therapy , Thromboembolism/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Aspirin/administration & dosage , Child , Child, Preschool , Clopidogrel , Contraindications , Drug Therapy, Combination , Female , Heparin, Low-Molecular-Weight/administration & dosage , Humans , Infant , Male , Middle Aged , Multivariate Analysis , Peritonitis/etiology , Pilot Projects , Postoperative Hemorrhage/etiology , Prognosis , Prospective Studies , Risk Factors , Surgical Wound Infection/etiology , Ticlopidine/administration & dosage , Ticlopidine/analogs & derivativesSubject(s)
Catheterization/adverse effects , Esophageal Perforation/therapy , Esophageal Stenosis/therapy , Esophagitis/therapy , Iatrogenic Disease , Stents , Child, Preschool , Esophageal Perforation/diagnosis , Esophageal Perforation/etiology , Esophageal Stenosis/chemically induced , Esophagitis/chemically induced , Female , Humans , Image Processing, Computer-Assisted , Sodium Hydroxide/poisoning , Tomography, X-Ray ComputedABSTRACT
Dynamic graciloplasty (DGP) and the Acticon Neosphincter (artificial bowel sphincter, ABS) are well-established therapeutic instruments in patients with severe fecal incontinence. However, the success rates in the literature must be interpreted with caution. The report presented here presents firstly a critical analysis of 1510 patients in 52 studies (29 DGP vs 23 ABS). The evidence of these studies was assessed using the Oxford EBM criteria. All data were statistically analysed. Up to 94% of the studies analysed show EBM levels of only >3b. Both procedures show significant improvements in postoperative continence scores (p<0.001) and a significant advantage of ABS over DGP. Nevertheless, they are associated with a high incidence of morbidity in the long term (infection rate ABS vs DGP 21.74% vs 35.1%, revision rate ABS vs DGP 37.53% vs 40.64%, and ABS explantation rates of 30%). Presently no therapeutic recommendation can be expressed based on the few data available. Furthermore, therapy should be performed in specialized centers and patients should be given a realistic picture of the critical outcome of both surgical techniques.
Subject(s)
Anal Canal/surgery , Fecal Incontinence/surgery , Muscle, Skeletal/transplantation , Prostheses and Implants , Electric Stimulation Therapy , Equipment Failure Analysis , Evidence-Based Medicine , Fecal Incontinence/etiology , Follow-Up Studies , Humans , Outcome and Process Assessment, Health Care , Postoperative Complications/etiology , Prosthesis DesignABSTRACT
The German Artificial Sphincter System GASS consists of a support ring which includes a fluid reservoir on the outer side and an occlusive cuff on the inner side. The cuffs are designed as polyurethane hollow bodies with a pre-determined inflation volume and are connected to an integrated piezo micropump/valve unit. To evaluate the threshold of continence, the GASS was placed around the anorectal junction via a perineal approach in one mini pig. The novel cuff design reduces the occlusion pressure and allows low compression volumes. Low operating pressures indicate a minor risk of ischemia injury of the bowel. The operation time is estimated at about 6 days with no recharging of the battery. The novel remote controlled GASS is a highly integrated prosthesis for placement around the anal canal or lower rectum and is effective in restoring continence for liquids and solids in vitro and in vivo.
